Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00075479" target="_blank" >RIV/00216224:14110/14:00075479 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/14:A1501CGD RIV/65269705:_____/14:00061495 RIV/00843989:_____/14:E0104311
Result on the web
<a href="http://dx.doi.org/10.1111/jcmm.12279" target="_blank" >http://dx.doi.org/10.1111/jcmm.12279</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/jcmm.12279" target="_blank" >10.1111/jcmm.12279</a>

Result language
angličtina
Original language name
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Original language description
Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre-clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second-generation of proteasome inhibitors (PIs) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second-generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)